达尔美替尼联合阿美替尼治疗EGFR-TKI耐药伴MET扩增晚期NSCLC的随机III期试验
这项随机、开放标签III期试验纳入314例EGFR突变、MET扩增的晚期NSCLC患者,在EGFR-TKI进展后按1:1随机接受达尔美替尼联合阿美替尼或含铂化疗。联合组中位PFS为6.2个月,化疗组为4.4个月(HR 0.60,95%CI 0.45-0.81,P<0.001),ORR分别为59.6%和38.6%,≥3级治疗相关不良事件发生率相似。
要点
- 达尔美替尼联合阿美替尼较含铂化疗显著改善EGFR-TKI耐药后MET扩增晚期NSCLC的PFS。
- 联合组ORR为59.6%,化疗组为38.6%;中位DoR分别为9.7个月和4.4个月。
- 两组≥3级治疗相关不良事件发生率分别为50.0%和51.0%,毒性谱不同。
核心结论
- 在EGFR-TKI进展后的EGFR突变、MET扩增晚期NSCLC中,达尔美替尼联合阿美替尼较含铂化疗显著改善PFS,安全性可控。
研究设计与样本
- 随机、开放标签III期试验(NCT06110663),纳入314例EGFR突变、MET扩增的局部晚期或转移性NSCLC患者,按1:1随机分配至达尔美替尼联合阿美替尼组(n=156)或含铂化疗组(n=158)。
- MET扩增由荧光原位杂交定义:平均MET拷贝数≥5或MET/CEP7比值≥2。
- 主要终点为盲态独立中心按RECIST 1.1评估的PFS;次要终点包括OS、ORR、DoR和安全性。
主要发现
- 联合组中位PFS为6.2个月,化疗组为4.4个月(HR 0.60;95%CI 0.45-0.81;P<0.001)。
- 联合组与化疗组ORR分别为59.6%和38.6%,中位DoR分别为9.7个月和4.4个月。
- OS数据尚不成熟。
- ≥3级治疗相关不良事件发生率分别为50.0%和51.0%;联合组肝脏实验室异常更多,化疗组血液学毒性更多。
关键数值与推荐
- MET扩增定义:平均MET拷贝数≥5或MET/CEP7比值≥2(FISH法)。
- 主要终点PFS:联合组6.2个月 vs 化疗组4.4个月,HR 0.60(95%CI 0.45-0.81),P<0.001。
- ORR:联合组59.6% vs 化疗组38.6%;中位DoR:9.7个月 vs 4.4个月。
- ≥3级治疗相关不良事件:联合组50.0% vs 化疗组51.0%。
临床怎么用
- 对于EGFR-TKI进展后经FISH确认MET扩增(平均MET拷贝数≥5或MET/CEP7比值≥2)的EGFR突变晚期NSCLC,可考虑达尔美替尼联合阿美替尼作为新的治疗选择。
- 治疗期间需关注联合方案相关的肝脏实验室异常,以及化疗相关的血液学毒性。
局限性
- OS数据尚不成熟,需更长期随访。
- 研究为开放标签设计。
- MET扩增定义依赖FISH,不同检测方法的一致性未在本文报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: MET amplification accounts for up to 30% of acquired resistance to EGFR-TKI, especially following third-generation EGFR-TKI treatment, yet precision-targeted therapeutic options remain limited. Early-phase studies demonstrated promising antitumor activity with the MET-TKI dalmelitinib combined with the third-generation EGFR-TKI aumolertinib. This phase 3 trial compared dalmelitinib-aumolertinib with platinum-based chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR-TKIs progression. PATIENTS AND METHODS: This randomized, open-label, phase 3 trial (NCT06110663) enrolled patients with locally advanced or metastatic EGFR-mutated, MET-amplified NSCLC after EGFR-TKI progression. MET amplification was defined by fluorescence in situ hybridization as a mean MET copy number ≥5 or MET/CEP7 ratio ≥2. Patients were randomly assigned (1:1) to dalmelitinib-aumolertinib or platinum-based chemotherapy groups. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review per RECIST 1.1. Secondary endpoints included overall survival, objective response rate (ORR), duration of response (DoR), and safety. RESULTS: A total of 314 enrolled patients were assigned to dalmelitinib-aumolertinib (n=156) or platinum-based chemotherapy (n=158). Median follow-up was 11.2 months at the data cutoff date (December 10, 2025). Median PFS was 6.2 months with dalmelitinib-aumolertinib and 4.4 months with chemotherapy (HR, 0.60; 95% CI, 0.45 to 0.81; P <0.001). Corresponding ORRs were 59.6% and 38.6%, and median DoRs were 9.7 months and 4.4 months, respectively. Overall survival data were immature. Grade ≥3 treatment-emergent adverse events occurred in 50.0% and 51.0% of patients, respectively. Toxicity profiles differed, with more hepatic laboratory abnormalities with dalmelitinib-aumolertinib and more hematologic toxicities with chemotherapy. CONCLUSION: The dalmelitinib-aumolertinib combination significantly improved PFS versus chemotherapy, with a manageable safety profile in advanced EGFR-mutated, MET-amplified NSCLC after progression on EGFR-TKI. These findings support dual EGFR/ MET inhibition as a new treatment option in this biomarker selected population.
引用
- Li Z, Dong X, Yu Y, et al. Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial. J Clin Oncol. 2026. PMID: 42928710. doi:10.1200/JCO-26-02432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。